Introduction {#S0001}
============

As a malignant tumor of mesenchymal origin, soft tissue sarcomas (STS) have a low incidence.[@CIT0001],[@CIT0002] However, approximately 40,000 incident cases of more than 70 STS subtypes are still reported in China annually.[@CIT0003],[@CIT0004] A significant proportion of STS will eventually metastasize,[@CIT0002],[@CIT0004] which primarily occurs through the blood and with the lung and liver being the most common sites for primary metastases.[@CIT0002],[@CIT0005] The first line of the treatment of advanced STS is doxorubicin-based chemotherapy.[@CIT0004],[@CIT0006],[@CIT0007] Multi-target receptor tyrosine kinase inhibitors (TKIs) have been shown to be effective against STS.[@CIT0008],[@CIT0009] However, most patients who receive chemotherapy or TKI-targeted therapy relapse after a certain period of time. The mean overall survival (OS) of metastatic STS after comprehensive treatment is 12 to 18 months.[@CIT0010] Therefore, more effective alternatives need to be developed.

Programmed cell death-1 (PD-1) targeted immunotherapy has been consistently shown to be effective in the treatment of advanced STS.[@CIT0011]--[@CIT0013] However, PD-1 inhibitors are ineffective as monotherapy for STS. In a multicenter, open-label, Phase II trial of the PD-1 inhibitor pembrolizumab for the treatment of patients with advanced STS and bone sarcomas, the objective response rate (ORR) of patients with STS was only 18% (7 out of 40 patients).[@CIT0011] In another non-comparative multicenter randomized Phase 2 trial of nivolumab (a PD-1 inhibitor) +/− ipilimumab for the treatment of patients with advanced sarcoma, the confirmed ORR was only 5% among 38 patients that received nivolumab monotherapy.[@CIT0012] The combination therapy of chemotherapy with PD-1 inhibitor has been proposed to improve the efficacy of PD-1 inhibitor against malignancies. The combination of PD-1 inhibitor and chemotherapy has been shown to be effective for the treatment of non-small cell lung cancer (NSCLC),[@CIT0014],[@CIT0015] breast cancer and nasopharyngeal cancer, with fewer adverse events (AEs).[@CIT0016],[@CIT0017] It has also been reported that doxorubicin can enhance the efficacy of PD-1 inhibitors.[@CIT0018] Accordingly, we combined PD-1 inhibitors with doxorubicin chemotherapy and started treating a cohort of patients with advanced STS since 2017. In this study, we aimed to assess the safety and efficacy of doxorubicin chemotherapy plus PD-1 inhibitor in the treatment of metastatic STS.

Materials and Methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

This was a single center retrospective study of 21 patients who received doxorubicin chemotherapy plus PD-1 inhibitor as treatment for STS between November 2017 and October 2018 at The Affiliated Cancer Hospital of Zhengzhou University. The inclusion criteria were as follows: (1) age 16 to 65 years; (2) histologically diagnosed nonspecific subtype STS; (3) acceptable blood, liver and kidney functions; (4) locally unresectable or multiple metastases; (5) interval of more than 3 months between the end of previous chemotherapy and enrollment; (6) The Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; (7) The target lesions were measurable according to the response evaluation criteria in solid tumors (RECIST), version 1.1.

This study was approved by the Ethics Committee for Clinical Investigation of The Affiliated Cancer Hospital of Zhengzhou University and was conducted according to the tenets of the Declaration of Helsinki. All patients provided written informed consent for data collection and research purposes.

Treatment Protocol {#S0002-S2002}
------------------

The initial patients received 200 mg pembrolizumab (Merck Sharp & Dohme Corp, USA), Patients later in the study received 200 mg camrelizumab (Hengrui Medicine, China) via a 30-min intravenous infusion on day 1 every 21 days until disease progression (PD) or the occurrence of unacceptable AEs. In parallel, patients were administered chemotherapy (37.5 mg/m^2^ doxorubicin per day via intravenous bolus) on days 2 and 3 every 21 days for a maximum of six cycles unless PD or AEs occurred. AEs were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0. The treatment was delayed until recovery when the patients developed grade 3 or 4 AEs. The treatment was terminated if the delay was more than 2 weeks.

Evaluation of Safety and Efficacy {#S0002-S2003}
---------------------------------

Efficacy was evaluated according to the RECIST 1.1 criteria every 30 or 60 days via magnetic resonance imaging or computed tomography. Anti-tumor efficacy was categorized as complete response (CR), partial response (PR), stable disease (SD) or PD, according to RECIST 1.1 criteria. The median progression-free survival (m-PFS), ORR, disease control rate (DCR) and AEs were also evaluated. PFS was defined as the time from the first day of treatment to the occurrence of PD or death, whichever occurred first.

Statistical Analysis {#S0002-S2004}
--------------------

All the data were analysed using SPSS 21.0 software. Quantitative variables are presented as numbers (percentage) or medians (range). PFS was calculated using the Kaplan-Meier method, with 95% confidence interval (CI). the corresponding figures were drawn by using GraphPad Prism 5.0. The cutoff date for data collection was October 2019, and the present study is a descriptive analysis.

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

The cohort included 9 (42.86%) men and 12 (57.14%) women. The average patient age was 45.81±18.25 years. The basic patient characteristics are as shown in [Table 1](#T0001){ref-type="table"}. All patients had stage IV disease. The primary tumor site varied greatly and was distributed throughout the body, but it was mainly in the extremities. All the target lesions were metastatic lesions. The histological subtypes were also markedly different, with the most common being synovial sarcoma (n=4) and undifferentiated pleomorphic sarcoma (UPS) (n=4) followed by angiosarcoma (n=2), clear cell sarcoma (n=2), malignant peripheral nerve sheath tumor (MPNST) (n=2), myxofibrosarcoma(n=2), and myxoid liposarcoma (n=2), and the least common being dedifferentiated liposarcoma (n=1), epithelioid sarcoma (n=1), and leiomyosarcoma (n=1). 66.67% (14/21) patients underwent excision of the primary lesion, and 28.58% (6/21) of patients were previously treated with doxorubicin. Sixteen patients received pembrolizumab, and five patients received camrelizumab.Table 1Patient Demographics and CharacteristicsPatient No.GenderAgeECOG PSHistological TypeStagePrimary SiteMetastatic SiteExcision of Primary LesionPrevious D ChemotherapyDrugBest ResponsePFS (Months)1Male521Clear cell sarcomaIVExtremitiesLymph nodesYesNoP+DPR72Female581UPSIVTrunkLungNoNoP+DCR183Female480MPNSTIVExtremitiesLungNoNoP+DPD14Male330Synovial sarcomaIVExtremitiesLungNoYesP+DPR105Female501Myxoid liposarcomaIVTrunkLiverYesYesP+DPD26Female591UPSIVExtremitiesLungYesYesP+DSD67Female480MyxofibrosarcomaIVExtremitiesLungYesNoP+DSD88Male630Synovial sarcomaIVExtremitiesLungNoNoP+DPR89Female450UPSIVRetroperitonealLiverYesYesP+DPR1210Male220AngiosarcomaIVTrunkBoneNoNoP+DCR2011Female290Synovial sarcomaIVExtremitiesLungYesNoP+DSD512Male281Epithelioid sarcomaIVExtremitiesLungYesNoP+DPD113Male580MyxofibrosarcomaIVTrunkLungNoNoP+DPD114Male601UPSIVExtremitiesLungYesYesP+DPR915Female610Synovial sarcomaIVExtremitiesLungYesNoP+DPR616Male520Clear cell sarcomaIVExtremitiesLymph nodesYesNoP+DSD317Female281AngiosarcomaIVHead and neckLungYesYesC+DPR718Female471LeiomyosarcomaIVExtremitiesLungYesNoC+DSD619Male541MPNSTIVExtremitiesLungNoNoC+DPD120Female380Myxoid liposarcomaIVRetroperitonealLungYesNoC+DPD221Female291Dedifferentiated liposarcomaIVExtremitiesBoneYesNoC+DPR13[^1]

Efficacy of Therapy {#S0003-S2002}
-------------------

Of the 21 patients, 2 patients (one with UPS and one with angiosarcoma) achieved CR; 8 patients had PR, 5 patients had SD and 6 patients had PD ([Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}). The ORR was 47.6%, the DCR was 71.4%, and the m-PFS was 6 months (95% CI, 2--8 months) ([Table 3](#T0003){ref-type="table"}). The Average change in target lesion diameter from baseline was −25.15 ± 41.61 ([Figure 1](#F0001){ref-type="fig"}). The Kaplan-Meier estimate of PFS is shown in [Figure 2](#F0002){ref-type="fig"}.Table 2Responses of Various Histological Subtypes to TreatmentHistological SubtypesNumber of PatientsCRPRSDPDUPS1210Synovial sarcoma0310Angiosarcoma1100Clear cell sarcoma0110Myxoid liposarcoma0002MPNST0002Myxofibrosarcoma0011Dedifferentiated liposarcoma0100Leiomyosarcoma0010Epithelioid sarcoma0001Total2856[^2] Table 3Clinical EfficacyCharacteristicsDataORR47.60%DCR71.40%m-PFS (months)6(95CI, 2--8)[^3][^4] Figure 1Waterfall plots show the maximum percentage change in target lesion size during active treatment. Horizontal dashed lines represent the criteria for progressive disease (20% increase in target lesion size) and partial response (30% decrease in target lesion size), as evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.**Abbreviations:** UPS, undifferentiated pleomorphic sarcoma; MPNST, malignant peripheral nerve sheath tumor.Figure 2Kaplan--Meier estimates of progression-free survival.

Toxicity and Safety {#S0003-S2003}
-------------------

In general, the combination therapy of PD-1 inhibitor immunotherapy and doxorubicin chemotherapy was relatively well tolerated. The majority of the AEs were grade 1 or 2, and grade 3 or 4 AEs were rare ([Table 4](#T0004){ref-type="table"}). No treatment-related deaths occurred. The most common grade 1/2 AEs were alopecia (90.5%), leukopenia (85.7%), anemia (76.2%), fatigue (76.2%), nausea (66.7%), and vomiting (47.6%). The most common grade 3/4 AEs were leukopenia (23.8%) and anemia (19.0%). The immune-related AEs included hypothyroidism (n=3, 14.3%, all three patients received camrelizumab), and pneumonitis (n=2, 9.5%, one received camrelizumab and another received pembrolizumab). Immune-related AEs were treated with prednisone, and all patients recovered accordingly. there were no treatment delays due to the AEs.Table 4Adverse EventsAdverse EventAll GradesGrade \>2Alopecia19(90.5%)0(0%)Leucopenia18(85.7%)5(23.8%)Anaemia16(76.2%)4(19.0%)Fatigue16(76.2%)1(4.8%)Nausea14(66.7%)0(0%)Vomiting10(47.6%)1(4.8%)Transaminase increase4(19.0%)1(4.8%)Anorexia4(19.0%)0(0%)Diarrhoea3(14.3%)1(4.8%)Fever3(14.3%)0(0%)Hypothyroidism3(14.3%)0(0%)Cough2(9.5%)1(4.8%)Pneumonitis2(9.5%)1(4.8%)Constipation2(9.5%)0(0%)Weight loss2(9.5%)0(0%)Pain1(4.8%)0(0%)Limb edema1(4.8%)0(0%)Pruritus1(4.8%)0(0%)Rash1(4.8%)0(0%)[^5]

Discussion {#S0004}
==========

This retrospective study evaluated the safety and efficacy of combination treatment of chemotherapy and PD-1 inhibitor (pembrolizumab or camrelizumab) for STS in a cohort of 21 patients with advanced-stage disease. The ORR was 47.6%, DCR was 71.4%, and m-PFS was 6 months (95% CI, 2--8 months). The average change of target lesion diameter from baseline was −25.15% ± 41.61%.

Doxorubicin-based chemotherapy remains the first line treatment for metastatic or locally unresectable STS, as recommended by the National Comprehensive Cancer Network guidelines.[@CIT0007] However, the efficacy of doxorubicin chemotherapy for STS is low.[@CIT0006],[@CIT0019] AEs and drug resistance have also limited the continued use of doxorubicin.[@CIT0020] Therefore, there is an urgent need for new systemic therapies for advanced STS. The emergence of broad-spectrum TKIs has made a significant progress in the treatment of those patients. However, broad-spectrum TKIs for advanced STS yields an ORR of only approximately 14% and an m-PFS of approximately 4.6 months.[@CIT0008],[@CIT0009] Fortunately, a 2017 phase II trial of pembrolizumab in advanced STS showed promising results.[@CIT0011] Since then, many patients with advanced STS in China started to use PD-1 inhibitors off-label, particularly due to the introduction of local and cheaper PD-1 inhibitors into the market.[@CIT0021],[@CIT0022] However, as shown in the phase 2 trial of pembrolizumab in STS, PD-1 inhibitor monotherapy has limited efficacy in most patients with advanced STS.

Increasing evidence shows that the anti-tumor effects of chemotherapy are mediated not only through cytotoxic effects, but also through stimulating and modulating tumor immunity by enhancing tumor antigen presentation, immunogenic cell death, and inhibiting regulatory T cells.[@CIT0018],[@CIT0023]--[@CIT0026] These results lend credence to the argument that the combination of chemotherapy and immunotherapy is the next step for cancer treatment. Based on these evidences and on the results of previous studies in other malignant tumors,[@CIT0027],[@CIT0028] we started using PD-1 inhibitors and doxorubicin in advanced STS.

We could not calculate the exact overall survival in this study because majority of the patients received other treatments after PD. Hence, PFS, ORR, and DCR were selected as endpoints. The ORR of PD-1 inhibitor plus doxorubicin treatment was higher than that of doxorubicin alone (14%) or PD-1 inhibitor alone (18%) reported in other studies.[@CIT0006],[@CIT0011] This suggests that doxorubicin may have a synergistic effect with PD-1 inhibitor. Our results are similar to those of the TONIC trial in breast cancer, which indicated that short-term doxorubicin may induce a more favorable tumor microenvironment and increased the likelihood of response to PD-1 inhibitor.[@CIT0018] The PFS in this study was also higher compared to that of monotherapy regimens reported in another study.[@CIT0006] As a cytotoxic chemotherapy drug, doxorubicin works rapidly, while PD-1 inhibitors have a later onset but a longer duration of action.[@CIT0011],[@CIT0015],[@CIT0028] When doxorubicin is combined with PD-1 inhibitor, the cytotoxic effect is achieved immediately from doxorubicin and is then maintained for long periods from the PD-1 inhibitor. From this perspective, these two drugs complement each other with respect to both effectiveness and duration.

The results of this study showed that the therapeutic effect of PD-1 inhibitor combined with doxorubicin differs according to the sarcoma subtype. The subtypes that responded well (including UPS, synovial sarcoma, and angiosarcoma) are all sensitive to at least one of the two drugs. Meanwhile, the subtypes that showed poor therapeutic response, such as MPNST, myxofibrosarcoma, and myxoid liposarcoma, appeared insensitive either to doxorubicin or PD-1 inhibitor. Studies have shown that in NSCLC treatment, the addition of standard chemotherapy to PD-1 inhibitor treatment resulted in a significant longer PFS and OS irrespective of PD-L1 expression.[@CIT0027],[@CIT0029] In other words, adding chemotherapy can increase the sensitivity of malignant tumors to PD-1 inhibitors. From this perspective, for sarcoma subtypes that showed poor sensitivity to either doxorubicin or PD-1 in this study, it may be beneficial to switch to chemotherapy drugs to which they may be sensitive to.

Compared with monotherapy, combination therapy was associated with more types of AEs in this study, but the severity did not increase significantly, consistent with other studies.[@CIT0006],[@CIT0011] The AEs observed were common grade 1--2 complications associated with chemotherapy or immunotherapy. There was no indication for increased frequency or severity of immune-related or chemotherapy-related AEs. However, immune-related thyroid disorders appear to be more common in patients treated with camrelizumab than in those treated with pembrolizumab, in line with other studies using camrelizumab.[@CIT0016],[@CIT0030] Because the number of patients in this study is too small, we cannot determine whether there is a significant difference in AEs between the two PD-1 inhibitors, and further studies are needed.

The combination of chemotherapy, targeted therapy, and immunotherapy in the treatment of advanced STS is logical. This study preliminarily demonstrated the safety and efficacy of doxorubicin combined with the PD-1 inhibitor. However, this study has some limitations, including its retrospective design, small sample size, the absence of a control group, and the inclusion of uncommon sarcoma subtypes. The optimal dose of chemotherapy drugs also needs to be further evaluated. To further investigate the efficacy of PD-1 inhibitor combined with doxorubicin in the treatment of sarcoma, we are soon conducting a randomised clinical trial (Chinese Clinical Trial Registry NO. ChiCTR1900027009).

Conclusion {#S0005}
==========

Our study has preliminarily demonstrated that the combination therapy of PD-1 inhibitor and doxorubicin is safe and effective for advanced STS, providing a basis for further studies investigating doxorubicin and PD-1 inhibitor combination regimens.
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[^1]: **Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival; UPS, undifferentiated pleomorphic sarcoma; MPNST, malignant perioheral nerve sheath tumor; P, pembrolizumab; D, doxorubicin; C, camrelizumab; PR, partial response; CR, complete response; PD, progressive disease; SD, stable disease.

[^2]: **Abbreviations:** CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; UPS, undifferentiated pleomorphic sarcoma; MPNST, malignant peripheral nerve sheath tumor.

[^3]: **Note:** Data are presented as percentages or means.

[^4]: **Abbreviations:** ORR, the objective response rate; DCR, the disease control rate; m-PFS, the median progression-free survival.

[^5]: **Note:** Data are presented as numbers (percentages).
